Hepatic Metastasis of Colorectal Cancer Clinical Trial
Official title:
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer: One-arm Exploratory Clinical Study
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and
radiofrequency ablation.
The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously
every 3weeks and 250mg apatinib mesylate qd ，and 850mg/m2 capecitabine d1-14 and 130mg/m2
oxaliplatin given intravenously d1.
;